<!DOCTYPE html>
<html lang="en">
	<head>
  		<meta charset="UTF-8">
  		<title>Bio2RDF - Drugbank</title>
		<link href="images/bio2rdf.png" rel="shortcut icon" />
		<link rel="stylesheet" type="text/css" href="css/style.css" media="screen" />
  		<script src="https://code.jquery.com/jquery-3.2.1.min.js"></script>
  		<script src="handlebars-v4.0.10.js"></script>
  		<!--<script src="https://cdnjs.cloudflare.com/ajax/libs/handlebars.js/4.0.10/handlebars.runtime.min.js"></script>-->
	
		<script type="application/ld+json">{
 "@context" : "http://schema.org",
  "@id" : "http://bio2rdf.org/drugbank:DB00187",
  "@type" : "Drug",
  "administrationRoute" : "intravenous",
  "availableStrength" : [ {
    "@id" : "http://bio2rdf.org/drugbank_resource:97eaae010cc670914ce7ace1f28a2a99",
    "@type" : "DrugStrength",
    "description" : "20 mg/mL Injection form with intravenous route"
  }, {
    "@id" : "http://bio2rdf.org/drugbank_resource:cafefd00cc918378a6d54b1dcc507fd1",
    "@type" : "DrugStrength",
    "description" : "10 mg/mL Injection, solution form with intravenous route"
  }, {
    "@id" : "http://bio2rdf.org/drugbank_resource:7c34039be71b18f949145d984739b858",
    "@type" : "DrugStrength",
    "description" : "10 mg/mL Injection form with intravenous route"
  } ],
  "cost" : [ {
    "@id" : "http://bio2rdf.org/drugbank_resource:c46dbcfd5c523f60dd479216eda55eb9",
    "@type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "2.2100000381469726562",
    "drugUnit" : "Brevibloc 10 mg/ml vial"
  }, {
    "@id" : "http://bio2rdf.org/drugbank_resource:fe7340110f1d545139b10c9c96ee5c67",
    "@type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "1.2599999904632568359",
    "drugUnit" : "Esmolol hcl 10 mg/ml vial"
  }, {
    "@id" : "http://bio2rdf.org/drugbank_resource:c207727c40fa5807e4e36d0a8439c40f",
    "@type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "1.5399999618530273438",
    "drugUnit" : "Brevibloc 20 mg/ml iv bag"
  }, {
    "@id" : "http://bio2rdf.org/drugbank_resource:7976bf62102e93d01807cefcd53c843a",
    "@type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "13.210000038146972656",
    "drugUnit" : "Brevibloc 250 mg/ml ampul"
  } ],
  "description" : "Esmolol (trade name Brevibloc) is a cardioselective beta1 receptor blocker with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages.\r\n\r\nEsmolol decreases the force and rate of heart contractions by blocking beta-adrenergic receptors of the sympathetic nervous system, which are found in the heart and other organs of the body. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine.",
  "dosageForm" : [ "Injection, solution", "Injection" ],
  "identifier" : "drugbank:DB00187",
  "interactingDrug" : [ "DDI between Esmolol and Risperidone - Hypotensive Agents may enhance the hypotensive effect of RisperiDONE.", "DDI between Esmolol and Tofacitinib - May enhance the bradycardic effect of Bradycardia-Causing Agents.", "DDI between Esmolol and Pentoxifylline - May enhance the hypotensive effect of Antihypertensives.", "DDI between Esmolol and Bretylium - May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.", "DDI between Esmolol and Mepivacaine - Beta-Blockers may increase the serum concentration of Mepivacaine.", "DDI between Esmolol and Propafenone - May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.", "DDI between Esmolol and Tadalafil - May enhance the antihypertensive effect of Antihypertensives.", "DDI between Esmolol and Primidone - May decrease the serum concentration of Beta-Blockers.", "DDI between Esmolol and Heptabarbital - May decrease the serum concentration of Beta-Blockers.", "DDI between Esmolol and Secobarbital - May decrease the serum concentration of Beta-Blockers.", "DDI between Esmolol and Methylphenidate - May diminish the antihypertensive effect of Antihypertensives.", "DDI between Esmolol and Lacosamide - Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide.", "DDI between Esmolol and Bupivacaine - Beta-Blockers may increase the serum concentration of Bupivacaine.", "DDI between Esmolol and Fingolimod - Beta-Blockers may enhance the bradycardic effect of Fingolimod.", "DDI between Esmolol and Acetylcholine - Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.", "DDI between Esmolol and Midodrine - Beta-Blockers may enhance the bradycardic effect of Midodrine.", "DDI between Esmolol and Methacholine - Beta-Blockers may enhance the adverse/toxic effect of Methacholine.", "DDI between Esmolol and Reserpine - May enhance the hypotensive effect of Beta-Blockers.", "DDI between Esmolol and Amiodarone - May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.", "DDI between Esmolol and Obinutuzumab - Antihypertensives may enhance the hypotensive effect of Obinutuzumab.", "DDI between Esmolol and Butabarbital - May decrease the serum concentration of Beta-Blockers.", "DDI between Rituximab and Esmolol - Antihypertensives may enhance the hypotensive effect of RiTUXimab.", "DDI between Esmolol and Hexobarbital - May decrease the serum concentration of Beta-Blockers.", "DDI between Esmolol and Regorafenib - May enhance the bradycardic effect of Beta-Blockers.", "DDI between Esmolol and Duloxetine - Hypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.", "DDI between Esmolol and Methohexital - May decrease the serum concentration of Beta-Blockers.", "DDI between Esmolol and Floctafenine - May enhance the adverse/toxic effect of Beta-Blockers.", "DDI between Esmolol and Butethal - May decrease the serum concentration of Beta-Blockers.", "DDI between Esmolol and Ruxolitinib - May enhance the bradycardic effect of Bradycardia-Causing Agents.", "DDI between Esmolol and Amifostine - Antihypertensives may enhance the hypotensive effect of Amifostine.", "DDI between Esmolol and Carbachol - Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.", "DDI between Esmolol and Disopyramide - May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may enhance the negative inotropic effect of Disopyramide.", "DDI between Esmolol and Diazoxide - May enhance the hypotensive effect of Antihypertensives.", "DDI between Esmolol and Yohimbine - May diminish the antihypertensive effect of Antihypertensives.", "DDI between Esmolol and Dipyridamole - May enhance the bradycardic effect of Beta-Blockers.", "DDI between Esmolol and Vardenafil - May enhance the antihypertensive effect of Antihypertensives.", "DDI between Esmolol and Dronedarone - May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6.", "DDI between Esmolol and Pentobarbital - May decrease the serum concentration of Beta-Blockers.", "DDI between Esmolol and Rivastigmine - May enhance the bradycardic effect of Beta-Blockers." ],
  "legalStatus" : "Approved",
  "manufacturer" : {
    "@id" : "http://bio2rdf.org/drugbank_resource:ef2c0d83723960c8ceb4d837d6cc6207",
    "@type" : "Organization",
    "name" : "Baxter healthcare corp anesthesia critical care"
  },
  "mechanismOfAction" : "Similar to other beta-blockers, esmolol blocks the agonistic effect of the sympathetic neurotransmitters by competing for receptor binding sites. Because it predominantly blocks the beta-1 receptors in cardiac tissue, it is said to be cardioselective. In general, so-called cardioselective beta-blockers are relatively cardioselective; at lower doses they block beta-1 receptors only but begin to block beta-2 receptors as the dose increases. At therapeutic dosages, esmolol does not have intrinsic sympathomimetic activity (ISA) or membrane-stabilizing (quinidine-like) activity. Antiarrhythmic activity is due to blockade of adrenergic stimulation of cardiac pacemaker potentials. In the Vaughan Williams classification of antiarrhythmics, beta-blockers are considered to be class II agents.",
  "name" : "Esmolol",
  "nonProprietaryName" : [ "Methyl P-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate", "Methyl 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoate", "(+-)-Methyl P-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate", "ESMOLOL", "(+-)-Esmolol", "3-[4-(2-Hydroxy-3-isopropylamino-propoxy)-phenyl]-propionic acid methyl ester" ],
  "sameAs" : [ "http://www.rxlist.com/cgi/generic3/esmolol.htm", "http://www.drugs.com/cdi/esmolol.html", "http://www.drugbank.ca/drugs/DB00187" ],
  "url" : "https://schemaorg.metadatacenter.org/drugbank/DB00187.html"
}</script>
	</head>

	<body>
		<br/><br/>
		
		<div id="all">
	 		<div id="main" style="text-align: center;">
	 			<div style="height: 20%;">&nbsp;</div>
	 			<img alt="Drugbank" src="images/drugbank.png" />
	 			<div id="main" style="text-align: center;">
	 				<em>Bio2RDF Drugbank Data</em>
				</div>

				<br/><br/>

			</div>

			<div id="contents">
				<script type="text/javascript">

				var templateCode = "<table><tbody><tr><td class='dataframeKey'>Drug Name</td><td>{{name}}</td></tr><tr><td class='dataframeKey'>Description</td><td>{{description}}</td></tr><tr><td class='dataframeKey'>Identifier</td><td>{{schema:identifier}}</td></tr><tr><td class='dataframeKey'>Non-Proprietary Names</td><td><ul>{{#each nonProprietaryName}}<li>{{this}}</li>{{else}}{{nonProprietaryName}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Proprietary Name</td><td>{{proprietaryName}}</td></tr><tr><td class='dataframeKey'>Drug Classes</td><td><ul>{{#each drugClass}}<li>{{this}}</li>{{else}}{{drugClass}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Clinical Pharmacology</td><td>{{clinicalPharmacology}}</td></tr><tr><td class='dataframeKey'>Manufacturer</td><td>{{#with manufacturer}}{{name}}{{/with}}</td></tr><tr><td class='dataframeKey'>Mechanism of Action</td><td>{{mechanismOfAction}}</td></tr><tr><td class='dataframeKey'>Food Warning</td><td>{{foodWarning}}</td></tr><tr><td class='dataframeKey'>URL</td><td><a href='{{schema:url}}'>{{schema:url}}</a></td></tr><tr><td class='dataframeKey'>Costs</td><td>{{#if cost.length}}<ul>{{#each cost}}<li>{{#with this}}{{drugUnit}} - {{costPerUnit}}{{costCurrency}}{{/with}}</li>{{/each}}</ul>{{else}}{{#with cost}}{{drugUnit}} - {{costPerUnit}}{{costCurrency}}{{/with}}{{/if}}</td></tr><tr><td class='dataframeKey'>Available Strength</td><td>{{#if availableStrength.length}}<ul>{{#each availableStrength}}<li>{{this.description}}</li>{{/each}}</ul>{{else}}{{#with availableStrength}}{{description}}{{/with}}{{/if}}</td></tr><tr><td class='dataframeKey'>Dosage Forms</td><td><ul>{{#each dosageForm}}<li>{{this}}</li>{{else}}{{dosageForm}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Administration Route</td><td><ul>{{#each administrationRoute}}<li>{{this}}</li>{{else}}{{administrationRoute}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Interacting Drugs</td><td><ul>{{#each interactingDrug}}<li>{{this}}</li>{{else}}{{interactingDrug}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Legal Statuses</td><td><ul>{{#each legalStatus}}<li>{{this}}</li>{{else}}{{legalStatus}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Same As</td><td><ul>{{#each sameAs}}<li><a href='{{this}}'>{{this}}</a></li>{{else}}<a href='{{sameAs}}'>{{sameAs}}</a>{{/each}}</ul></td></tr></tbody></table>";
				var template = Handlebars.compile(templateCode);

				$.getJSON("jsonld/DB00187.json", function(data) {
			    	document.getElementById("contents").innerHTML += template(data);
				});
		
				</script>
			</div>
		</div>
	</body>
</html>